The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam

Here, we show that the synaptic vesicle protein SV2A is the brain binding site of levetiracetam (LEV), a new antiepileptic drug with a unique activity profile in animal models of seizure and epilepsy. The LEV-binding site is enriched in synaptic vesicles, and photoaffinity labeling of purified synap...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Lynch, Berkley A., Lambeng, Nathalie, Nocka, Karl, Kensel-Hammes, Patricia, Bajjalieh, Sandra M., Matagne, Alain, Fuks, Bruno
Formato: Artigo
Idioma:Inglês
Publicado: National Academy of Sciences 2004
Assuntos:
Biological Sciences
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC470764/
https://ncbi.nlm.nih.gov/pubmed/15210974
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0308208101
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares